Physician

Robert K Roush, M.D.

According to 2025 Medicare claims, Robert Roush, M.D. (NPI: 1508801085) practices hematology/oncology in the Philadelphia, PA market, with the plurality of this provider's patient population coming from Delaware, PA. This provider's primary affiliated billing organization is CONSULTANTS IN MEDICAL ONCOLOGY & HEMATOLOGY, PC (NPI: 1043265820; TIN: 23-2826618) and primary practice location at 19342-1032.

Roush's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 563 traditional Medicare patients, billed 179,207 HCPCS/CPT codes, and received $2,525,579 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 1,501 prescription claims across 247 beneficiaries totaling $4,025,937 in drug costs, led by Revlimid (Lenalidomide). DME data shows 30 claims. Open Payments data shows 95 records totaling $2,075. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $1,472,840 to $2,525,579. Similarly, Part D prescription costs have moved sharply higher in recent years, from $1,246,253 to $4,025,937. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	351	164,268	$1,472,840
2016	378	128,099	$1,337,201
2017	382	107,878	$1,709,443
2018	386	118,369	$1,999,393
2019	406	126,079	$1,945,130
2020	463	144,869	$1,629,001
2021	493	216,876	$2,527,559
2022	482	240,262	$2,886,239
2023	519	202,789	$3,198,765
2024	563	179,207	$2,525,579

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	144	930	$1,246,253
2016	154	926	$872,802
2017	160	1,065	$1,577,371
2018	163	1,141	$2,050,686
2019	201	1,314	$1,978,316
2020	208	1,359	$2,976,472
2021	241	1,743	$3,969,229
2022	245	1,806	$4,565,282
2023	281	1,778	$4,878,767
2024	247	1,501	$4,025,937

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	52	$22,016
2016	N/R	40	$17,686
2017	N/R	42	$15,702
2018	N/R	18	$339
2019	N/R	32	$5,630
2020	N/R	N/R	N/R
2021	N/R	45	$4,924
2022	N/R	35	$1,538
2023	N/R	29	$7,038
2024	N/R	30	$838

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	116	263	$138
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	431	1,218	$97
36415	Insertion of needle into vein for collection of blood sample	356	982	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	406	1,463	$8
J3490	Unclassified drugs	101	348	$1

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	42	1,176	$717,998
Brukinsa	Zanubrutinib	27	810	$404,557
Tagrisso	Osimertinib Mesylate	14	420	$388,304
Welireg	Belzutifan	13	390	$383,849
Erleada	Apalutamide	22	660	$313,788

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	14	$537
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	16	$301

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	95	$2,075	ABBVIE INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Robert K. Roush, M.D.?

Tedicare shows public-source Medicare data for Robert K. Roush, M.D. (NPI 1508801085), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Robert K. Roush, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Robert K. Roush, M.D.?

Robert K. Roush, M.D. is linked to CONSULTANTS IN MEDICAL ONCOLOGY & HEMATOLOGY, PC (billing NPI 1043265820) in the available physician profile data.

Does Robert K. Roush, M.D. have Open Payments data?

Robert K. Roush, M.D. has 95 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.